PMCB Stock Overview
A biotechnology company, develops and commercializes cellular therapies for cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PharmaCyte Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.64 |
| 52 Week High | US$2.58 |
| 52 Week Low | US$1.39 |
| Beta | -0.23 |
| 1 Month Change | -3.53% |
| 3 Month Change | -7.87% |
| 1 Year Change | -26.79% |
| 3 Year Change | -39.03% |
| 5 Year Change | -97.23% |
| Change since IPO | -99.27% |
Recent News & Updates
Recent updates
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business
Mar 22
PharmaCyte Biotech says CEO to step down, announces strategic review of business
Oct 07PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors
Aug 15Is This A Good Time To Invest In PharmaCyte?
Jan 07PharmaCyte Biotech: Buy The 'Dump'
Aug 21Shareholder Returns
| PMCB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | -3.6% | -2.4% |
| 1Y | -26.8% | -2.6% | 23.4% |
Return vs Industry: PMCB underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: PMCB underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| PMCB volatility | |
|---|---|
| PMCB Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PMCB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PMCB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2 | Josh Silverman | pharmacyte.com |
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors.
PharmaCyte Biotech, Inc. Fundamentals Summary
| PMCB fundamental statistics | |
|---|---|
| Market cap | US$11.43m |
| Earnings (TTM) | US$9.42m |
| Revenue (TTM) | n/a |
1.2x
P/E Ratio0.0x
P/S RatioIs PMCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMCB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$9.42m |
| Earnings | US$9.42m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PMCB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaCyte Biotech, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward White | H.C. Wainwright & Co. |
| Dan Trang | Stonegate Capital Markets, Inc. |